A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

  • Robert Marcus
  • , R. Aultman*
  • , F. Jost
    • *Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    14 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science